# Study Evaluating Emergency-use Tigecycline in Subjects With Resistant Pathogens.

> **NCT00205816** · PHASE3 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 26 (actual)

## Conditions studied

- Bacterial Infections

## Interventions

- **DRUG:** Tigecycline

## Key facts

- **NCT ID:** NCT00205816
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2005-11
- **Final completion:** 2005-11
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2013-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00205816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00205816, "Study Evaluating Emergency-use Tigecycline in Subjects With Resistant Pathogens.". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00205816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*